Servier's Voranigo (vorasidenib), a first-in-class targeted therapy for isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant diffuse glioma, received approval from the U.S. Food and Drug Administration (FDA) in August 2024. This approval marks a significant development for patients with this form of brain cancer, offering a new treatment option.
For Royalty Pharma, this regulatory milestone translates into a new revenue stream. Royalties on Voranigo are expected to be recorded in Royalty Receipts starting in the fourth quarter of 2024, based on third quarter 2024 U.S. net sales.
The addition of Voranigo to Royalty Pharma's portfolio enhances its diversified royalty interests and is anticipated to contribute to the company's long-term growth in recurring cash inflows.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.